Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bi-Weekly Temozolomide Plus Bevacizumab for Recurrent Glioblastoma
NCT00883298Phase 2Completed
- Sponsor
- Center for Neurosciences
- Start
- Apr 2009
- Primary completion
- Dec 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in glioblastoma (GBM), Gliosarcoma (GS), sponsored by Center for Neurosciences. Started Apr 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT00883298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00883298.